Corpus Engine Towards a reproducible .science file.
← All .science files

pmid:34123798

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades.

Xiaoyan Wang · Bingchen Wu · Zhengqing Yan · Guoqiang Wang · Shiqing Chen · Jian Zeng · Feng Tao · Bichun Xu · Honggang Ke · Mei Li

Frontiers in oncology · 2021 doi:10.3389/fonc.2021.650122

Paper

complete

Experiment

partial

Data

partial

Analysis

complete

Execution

absent

Execution evidence has not yet been added to this .science file. Explore its methods, data and open questions to plan the next step.
Record details sci_version · id · kind · revision · content_hash · schema · created_at · updated_at · generator
id
pmid:34123798
kind
science-record
content_hash
sha256:1ef0e142558dab1af77d1e9b0813c00be703fcb3b39a3b7a5e9ad03caa91a127
schema
https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json
created_at
2026-11-01T15:41:38Z
updated_at
2026-11-01T21:25:30Z
generator object · 2 fields
name
corpus-assay-engine
run_id
reading-sci-2026-11-01
paper object · 10 fields
state
complete
title
Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades.
doi
10.3389/fonc.2021.650122
pmid
34123798
authors array · 10 items
[0]
Xiaoyan Wang
[1]
Bingchen Wu
[2]
Zhengqing Yan
[3]
Guoqiang Wang
[4]
Shiqing Chen
[5]
Jian Zeng
[6]
Feng Tao
[7]
Bichun Xu
[8]
Honggang Ke
[9]
Mei Li
journal
Frontiers in oncology
year
2021
abstract
The common gamma receptor-dependent cytokines and their JAK-STAT pathways play important roles in T cell immunity and have been demonstrated to be related with response to immune checkpoint blockades (ICBs). PTPRD and PTPRT are phosphatases involved in JAK-STAT pathway. However, their clinical significance for non-small cell lung cancer (NSCLC) treated with ICBs is still unclear. Genomic and survival data of NSCLC patients administrated with anti-PD-1/PD-L1 or anti-CTLA-4 antibodies (Rizvi2015; Hellmann2018; Rizvi2018 Samstein2019) were retrieved from publicly accessible data. Genomic, survival and mRNA data of 1007 patients with NSCLC were obtained from The Cancer Genome Atlas (TCGA). PTPRD/PTPRT mutation was significantly associated with better progression-free survival (PFS) in three independent Rizvi2015, Hellmann2018 and Rizvi2018 cohorts. The median PFS for PTPRD/PTPRT mutant-type vs. wild-type NSCLC patients were not reached vs. 6.3 months (Rizvi2015, HR = 0.16; 95% CI, 0.02-1.17; P=0.03), 24.0 vs. 5.4 months (Hellmann2018, HR, 0.49; 95% CI, 0.26-0.94; P=0.03), 5.6 vs. 3.0 months (Rizvi2018, HR = 0.64; 95% CI, 0.44-0.92; P=0.01) and 6.8 vs. 3.5 months (Pooled cohort, HR, 0.54; 95% CI, 0.39-0.73; P<0.0001) respectively. PTPRD/PTPRT mutation was an independent predictive factor for PFS in pooled cohort (P = 0.01). Additionally, PTPRD/PTPRT mutation associated with better overall survival (OS) in Samstein2019 cohort (19 vs. 10 months, P=0.03). While similar clinical benefits were not observed in patients without ICBs treatment (TCGA cohort, P=0.78). In the further exploratory analysis, PTPRD/PTPRT mutation was significantly associated with increased tumor mutation burden and higher mRNA expression of JAK1 and STAT1. Gene Set Enrichment Analysis revealed prominent enrichment of signatures related to antigen processing and presentation in patients with PTPRD/PTPRT mutation. This work suggested that PTPRD/PTPRT mutation might be a potential positive predictor for ICBs in NSCLC. These results need to be further confirmed in future.
claims array · 2 items
[0] object · 6 fields
id
claim-method
statement
The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model.
kind
methodological
target
null
evidence array · 2 items
[0] object · 3 fields
asset
source:pmid:34123798
locator
sections[5] "Statistical Analyses" paragraph 2
quote
The associations between PFS and various variables were examined by univariable and multivariable regression analysis.
[1] object · 3 fields
asset
source:pmid:34123798
locator
sections[5] "Statistical Analyses" paragraph 2
quote
Hazard’s ratio (HR) was determined through a cox proportional hazards regression model.
state
complete
[1] object · 6 fields
id
claim-data-access
statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material .
kind
methodological
target
null
evidence array · 1 item
[0] object · 3 fields
asset
source:pmid:34123798
locator
sections[13] "Data Availability Statement" paragraph 2
quote
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material .
state
complete
gaps array · 0 items
experiment object · 8 fields
state
partial
objective
null
steps array · 3 items
[0] object · 13 fields
id
read_published_estimate
order
1
name
Read the published estimate from the source
kind
other
state
complete
blocked_on
null
description
The claim, method and evidence span published with the source article.
parameters object · 0 fields
inputs array · 1 item
[0]
source:pmid:34123798
outputs array · 1 item
[0]
the published estimate and its evidence
instruments array · 0 items
reagents array · 0 items
[1] object · 13 fields
id
obtain_source_data
order
2
name
Obtain the source data from the named repository
kind
data-preparation
state
blocked
blocked_on
data:accession_absent
description
The GEO series accession resolves and its sample accessions are listed. This lane did not download the dataset or read its licence.
parameters object · 0 fields
inputs array · 0 items
outputs array · 1 item
[0]
the source data with its repository provenance
instruments array · 0 items
reagents array · 0 items
[2] object · 13 fields
id
run_analysis
order
3
name
Run the published analysis
kind
analysis
state
complete
blocked_on
null
description
Apply the paper's statistical method to the resolved series and compare the result with the published target.
parameters object · 0 fields
inputs array · 0 items
outputs array · 1 item
[0]
the replicated result and its comparison
instruments array · 0 items
reagents array · 0 items
materials array · 0 items
instruments array · 0 items
reagents array · 0 items
conditions object · 0 fields
gaps array · 1 item
[0]
step:obtain_source_data blocked on data:accession_absent
data object · 3 fields
state
partial
assets array · 3 items
[0] object · 15 fields
id
source:pmid:34123798
role
manuscript
format
xml
media_type
application/xml
uri
https://doi.org/10.3389/fonc.2021.650122
sha256
sha256:a740dc3207dd79086d5d5e07b81b1b95669d53b687ba33ba9cc959038595d2f0
bytes
35969
access
open
state
resolved
reader
null
reader_status
reader_required
identifier
10.3389/fonc.2021.650122
version
null
note
Full article fetched from PMC; the checksum covers the rendered section body, not the original XML bytes.
structure object · 4 fields
pmcid
PMC8192300
source
europe_pmc_fulltext
coverage
whole_body
text_hash_scope
rendered_section_body
[1] object · 16 fields
id
asset:table:pmid:34123798:1
role
table
format
jats-table
media_type
application/vnd.jats.table+json
uri
null
sha256
sha256:1c5700fd5ecbb8bbb34805eff0f42670849a8f7f9828b91851081ecc529874cb
bytes
1548
access
open
state
verified
reader
read_table
reader_status
available
identifier
section[7]/table-wrap[1]#T1
version
null
note
Baseline characteristics of NSCLC patients in Rizvi2015, Hellmann2018, Rizvi2018 and pooled cohorts.
structure object · 5 fields
pmcid
PMC8192300
section_index
7
section_title
Association Between PTPRD/PTPRT Mutation and Better PFS in NSCLC Patients Who Received ICBs Therapy From Three Independent Cohorts
row_count
25
column_count
5
table object · 8 fields
label
Table 1
caption
Baseline characteristics of NSCLC patients in Rizvi2015, Hellmann2018, Rizvi2018 and pooled cohorts.
rows array · 25 items
[0] array · 5 items
[0]
Characteristics
[1]
Rizvi2015
[2]
Hellmann2018
[3]
Rizvi2018
[4]
Pooled Cohort
[1] array · 5 items
[0]
Total n
[1]
34
[2]
75
[3]
240
[4]
349
[2] array · 5 items
[0]
Age, median (range)
[1]
62.5 (41-80)
[2]
66 (42-87)
[3]
66 (22-92)
[4]
65 (22-92)
[3] array · 5 items
[0]
Sex
[1]
[2]
[3]
[4]
[4] array · 5 items
[0]
Male
[1]
16 (47%)
[2]
37 (49%)
[3]
118 (49%)
[4]
171 (49%)
[5] array · 5 items
[0]
Female
[1]
18 (53%)
[2]
38 (51%)
[3]
122 (51%)
[4]
178 (51%)
[6] array · 5 items
[0]
Cancer type n (%)
[1]
[2]
[3]
[4]
[7] array · 5 items
[0]
Adenocarcinoma
[1]
34 (100%)
[2]
59 (79%)
[3]
186 (78%)
[4]
279 (80%)
[8] array · 5 items
[0]
Squamous
[1]
0 (0%)
[2]
16 (21%)
[3]
34 (14%)
[4]
50 (14%)
[9] array · 5 items
[0]
Others
[1]
0 (0%)
[2]
0 (%)
[3]
20 (8%)
[4]
20 (6%)
[10] array · 5 items
[0]
Agent
[1]
[2]
[3]
[4]
[11] array · 5 items
[0]
PD-(L)1
[1]
34 (100%)
[2]
0 (0%)
[3]
206(86%)
[4]
240 (0%)
[12] array · 5 items
[0]
PD-(L)1+CTLA-4
[1]
0 (0%)
[2]
75 (100%)
[3]
34(14%)
[4]
109 (100%)
[13] array · 5 items
[0]
Smoking history, n (%)
[1]
[2]
[3]
[4]
[14] array · 5 items
[0]
Current/former
[1]
28 (82%)
[2]
60 (80%)
[3]
193 (80%)
[4]
281 (80%)
[15] array · 5 items
[0]
Never
[1]
6 (18%)
[2]
15 (20%)
[3]
47 (20%)
[4]
68 (20%)
[16] array · 5 items
[0]
PDL1_expression
[1]
[2]
[3]
[4]
[17] array · 5 items
[0]
≥1%
[1]
24 (70%)
[2]
45 (60%)
[3]
43 (18%)
[4]
112 (32%)
[18] array · 5 items
[0]
0%
[1]
6 (18%)
[2]
25 (33%)
[3]
41 (17%)
[4]
72 (21%)
[19] array · 5 items
[0]
Unknown
[1]
4 (12%)
[2]
5 (7%)
[3]
156 (65%)
[4]
165 (47%)
[20] array · 5 items
[0]
Gene, n (%)
[1]
[2]
[3]
[4]
[21] array · 5 items
[0]
PTPRD mutation
[1]
3 (9%)
[2]
16 (21%)
[3]
30 (13%)
[4]
49 (14%)
[22] array · 5 items
[0]
PTPRT mutation
[1]
2 (6%)
[2]
9 (12%)
[3]
23 (10%)
[4]
34 (10%)
[23] array · 5 items
[0]
PTPRD/PTPRT mutation
[1]
5 (15%)
[2]
22 (29%)
[3]
47 (20%)
[4]
74 (21%)
[24] array · 5 items
[0]
PTPRD/PTPRT wild-type
[1]
29 (85%)
[2]
53 (71%)
[3]
193 (80%)
[4]
275 (79%)
locator
section[7]/table-wrap[1]#T1
[2] object · 16 fields
id
asset:table:pmid:34123798:2
role
table
format
jats-table
media_type
application/vnd.jats.table+json
uri
null
sha256
sha256:d4b7f9d1b42adcac7d5162b43c12d7ec8abdd638f08381e803f51d4bbe75dfdc
bytes
2943
access
open
state
verified
reader
read_table
reader_status
available
identifier
section[7]/table-wrap[2]#T2
version
null
note
Univariable and multivariable analyses of progression-free survival.
structure object · 5 fields
pmcid
PMC8192300
section_index
7
section_title
Association Between PTPRD/PTPRT Mutation and Better PFS in NSCLC Patients Who Received ICBs Therapy From Three Independent Cohorts
row_count
39
column_count
5
table object · 8 fields
label
Table 2
caption
Univariable and multivariable analyses of progression-free survival.
rows array · 39 items
[0] array · 1 item
[0]
Rizvi2015
[1] array · 3 items
[0]
Parameter
[1]
Univariable Analysis
[2]
Multivariable Analysis
[2] array · 4 items
[0]
HR (95%CI)
[1]
P value
[2]
HR (95%CI)
[3]
P value
[3] array · 5 items
[0]
Age ≥65 vs. <65 y
[1]
0.82 (0.33-2.01)
[2]
0.66
[3]
1.05 (0.33-3.38)
[4]
0.93
[4] array · 5 items
[0]
Male vs. female
[1]
1.75 (0.75-4.07)
[2]
0.20
[3]
1.09 (0.36-3.36)
[4]
0.88
[5] array · 5 items
[0]
Current or former vs. never smoker
[1]
0.60 (0.22-1.64)
[2]
0.32
[3]
0.67 (0.16-2.91)
[4]
0.60
[6] array · 5 items
[0]
TMB≥median vs. <median
[1]
0.21 (0.08-0.55)
[2]
0.002
[3]
0.20 (0.06-0.67)
[4]
0.01
[7] array · 5 items
[0]
PD-L1 status ≥1% vs. <1%
[1]
0.38 (0.14-1.01)
[2]
0.05
[3]
0.98 (0.33-2.98)
[4]
0.98
[8] array · 5 items
[0]
PTPRD/PTPRT mutant vs. wild
[1]
0.16 (0.02-1.17)
[2]
0.07
[3]
0.23 (0.03-2.04)
[4]
0.18
[9] array · 5 items
[0]
Lines of therapy ≥3 vs. <3
[1]
1.24 (0.53-2.91)
[2]
0.62
[3]
1.79 (0.46-6.93)
[4]
0.40
[10] array · 1 item
[0]
Hellmann2018
[11] array · 3 items
[0]
Parameter
[1]
Univariable Analysis
[2]
Multivariable Analysis
[12] array · 4 items
[0]
HR (95%CI)
[1]
P value
[2]
HR (95%CI)
[3]
P value
[13] array · 5 items
[0]
Age ≥65 vs. <65 y
[1]
0.89 (0.51-1.55)
[2]
0.67
[3]
0.71 (0.37-1.36)
[4]
0.31
[14] array · 5 items
[0]
Male vs. female
[1]
1.03 (0.59-1.80)
[2]
0.92
[3]
1.03 (0.55-1.91)
[4]
0.94
[15] array · 5 items
[0]
Current or former vs. never smoker
[1]
0.70 (0.36-1.36)
[2]
0.29
[3]
0.78 (0.37-1.64)
[4]
0.51
[16] array · 5 items
[0]
TMB≥median vs. <median
[1]
0.49 (0.28-0.87)
[2]
0.02
[3]
0.59 (0.28-1.22)
[4]
0.16
[17] array · 5 items
[0]
PD-L1 status ≥1% vs. <1%
[1]
0.86 (0.47-1.59)
[2]
0.63
[3]
1.04 (0.52-2.07)
[4]
0.92
[18] array · 5 items
[0]
PTPRD/PTPRT mutant vs. wild
[1]
0.47 (0.24-0.92)
[2]
0.03
[3]
0.59 (0.24-1.47)
[4]
0.25
[19] array · 1 item
[0]
Rizvi2018
[20] array · 3 items
[0]
Parameter
[1]
Univariable Analysis
[2]
Multivariable Analysis
[21] array · 4 items
[0]
HR (95%CI)
[1]
P value
[2]
HR (95%CI)
[3]
P value
[22] array · 5 items
[0]
Age ≥65 vs. <65 y
[1]
1.14 (0.86-1.52)
[2]
0.35
[3]
1.12 (0.69-1.81)
[4]
0.66
[23] array · 5 items
[0]
Male vs. female
[1]
1.09 (0.83-1.44)
[2]
0.54
[3]
0.88 (0.53-1.44)
[4]
0.60
[24] array · 5 items
[0]
Current or former vs. never smoker
[1]
0.69 (0.49-0.97)
[2]
0.03
[3]
0.59 (0.30-1.17)
[4]
0.13
[25] array · 5 items
[0]
TMB≥median vs. <median
[1]
0.65 (0.49-0.86)
[2]
0.003
[3]
0.94 (0.52-1.69)
[4]
0.84
[26] array · 5 items
[0]
PD-L1 status ≥1% vs. <1%
[1]
0.58 (0.36-0.92)
[2]
0.02
[3]
0.52 (0.31-0.88)
[4]
0.01
[27] array · 5 items
[0]
PTPRD/PTPRT mutant vs. wild
[1]
0.64 (0.44-0.92)
[2]
0.02
[3]
0.43 (0.20-0.92)
[4]
0.03
[28] array · 5 items
[0]
Lines of therapy ≥3 vs. <3
[1]
1.37 (1.00-1.88)
[2]
0.05
[3]
1.25 (0.70-2.20)
[4]
0.45
[29] array · 1 item
[0]
All NSCLC in pooled cohort
[30] array · 3 items
[0]
Parameter
[1]
Univariable Analysis
[2]
Multivariable Analysis
[31] array · 4 items
[0]
HR (95%CI)
[1]
P value
[2]
HR (95%CI)
[3]
P value
[32] array · 5 items
[0]
Age ≥65 vs. <65 y
[1]
1.06 (0.83-1.35)
[2]
0.64
[3]
0.95 (0.67-1.35)
[4]
0.78
[33] array · 5 items
[0]
Male vs. female
[1]
1.13 (0.89-1.44)
[2]
0.31
[3]
1.00 (0.71-1.41)
[4]
0.99
[34] array · 5 items
[0]
Current or former vs. never smoker
[1]
0.70 (0.52-0.93)
[2]
0.01
[3]
0.63 (0.41-0.97)
[4]
0.04
[35] array · 5 items
[0]
TMB≥median vs. <median
[1]
0.56 (0.44-0.72)
[2]
<0.001
[3]
0.62 (0.42-0.92)
[4]
0.02
[36] array · 5 items
[0]
PD-L1 status ≥1% vs. <1%
[1]
0.60 (0.43-0.84)
[2]
0.003
[3]
0.67 (0.47-0.96)
[4]
0.03
[37] array · 5 items
[0]
PTPRD/PTPRT mutant vs. wild
[1]
0.54 (0.39-0.73)
[2]
<0.001
[3]
0.52 (0.31-0.87)
[4]
0.01
[38] array · 5 items
[0]
lines of therapy ≥3 vs. <3
[1]
0.88 (0.69-1.12)
[2]
0.30
[3]
0.80 (0.56-1.13)
[4]
0.21
locator
section[7]/table-wrap[2]#T2
gaps array · 0 items
analysis object · 4 fields
state
complete
methods array · 2 items
[0] object · 10 fields
id
method-1
family
survival_analysis
specific
cox_proportional_hazards
label
Survival analysis
dsl_operations array · 1 item
[0]
cox_ph
missing_operations array · 0 items
parameters object · 0 fields
data_shapes array · 1 item
[0]
time_to_event_with_censoring
evidence object · 3 fields
score
1
band
reordered
quote
The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model.
[1] object · 10 fields
id
method-2
family
survival_analysis
specific
kaplan_meier
label
Survival analysis
dsl_operations array · 1 item
[0]
survival_km
missing_operations array · 0 items
parameters object · 0 fields
data_shapes array · 1 item
[0]
time_to_event_with_censoring
evidence object · 3 fields
score
0.8
band
high
quote
Kaplan-Meier
targets array · 0 items
gaps array · 0 items
capability object · 3 fields
state
complete
requirements array · 1 item
[0] object · 6 fields
capability_id
capability:computational_analysis
label
Computational analysis platform
assay_families array · 9 items
[0]
meta_analysis
[1]
machine_learning
[2]
survival_analysis
[3]
statistical_regression
[4]
pca
[5]
molecular_docking
[6]
network_analysis
[7]
differential_expression
[8]
gwas
candidate
Automated Assays Laravel application and simulated adapters
gaps array · 0 items
readiness object · 8 fields
state
blocked
tier
R4
blocked_on
data:accession_absent
axes object · 3 fields
method object · 5 fields
tier
R1
expressible
true
required_operations array · 1 item
[0]
cox_ph
missing_operations array · 0 items
basis
The paper names the method it used and the corpus's method extractor maps it onto the DSL catalogue: cox_proportional_hazards.
capability object · 4 fields
tier
R1
capability_id
capability:computational_analysis
availability_state
owned
basis
The computational analysis is owned. The physical bench the paper used is not, so a physical validation cannot be run here.
data object · 6 fields
tier
R4
reachable
false
accessions array · 0 items
resolved_accessions array · 0 items
statements array · 1 item
[0]
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material .
basis
The paper names no accession to its source data, so the data has to come from the authors.
can_run object · 3 fields
dsl_operations array · 1 item
[0]
cox_ph
assets array · 3 items
[0]
source:pmid:34123798
[1]
asset:table:pmid:34123798:1
[2]
asset:table:pmid:34123798:2
steps array · 1 item
[0]
run_analysis
must_build object · 5 fields
dsl_operations array · 0 items
converters array · 0 items
readers array · 0 items
capabilities array · 0 items
data_gaps array · 1 item
[0]
data:geo:None
gaps array · 1 item
[0]
data:accession_absent
review object · 5 fields
state
partial
machine_critique object · 5 fields
kind
extraction_review
reader object · 5 fields
model
MiniMax-M3.1-Flash
provider
minimax
provider_family
minimax
read_at
2026-10-31T18:30:51Z
independence
single_reader
evidence_check object · 2 fields
method
reordered
availability
verbatim
calls
3
usage object · 3 fields
prompt_tokens
30901
completion_tokens
1352
cached_tokens
784
stages array · 1 item
[0] object · 4 fields
id
extraction
state
complete
reader
MiniMax-M3.1-Flash
provider
minimax
gaps array · 3 items
[0]
review.independent_reader
[1]
review.machine_critique
[2]
review.human_critique
execution object · 5 fields
state
absent
status
not_run
mode
null
runs array · 0 items
gaps array · 1 item
[0]
execution.not_run
provenance object · 7 fields
entities array · 3 items
[0] object · 3 fields
id
pmid:34123798
type
paper
label
pmid:34123798
[1] object · 3 fields
id
source:pmid:34123798
type
manuscript
label
PMID 34123798 full text
[2] object · 3 fields
id
data:geo:None
type
dataset
label
GEO None
activities array · 3 items
[0] object · 4 fields
id
activity-reading-sci-2026-11-01
type
classification
used array · 3 items
[0] object · 3 fields
id
pmid:34123798
type
paper
label
pmid:34123798
[1] object · 3 fields
id
source:pmid:34123798
type
manuscript
label
PMID 34123798 full text
[2] object · 3 fields
id
data:geo:None
type
dataset
label
GEO None
agent
agent:corpus-assay-engine
[1] object · 4 fields
id
activity-read-34123798
type
extraction
used array · 1 item
[0]
source:pmid:34123798
agent
agent:minimax-reader
[2] object · 4 fields
id
activity-resolve-None
type
accession_resolution
used array · 1 item
[0]
data:geo:None
agent
agent:corpus-assay-engine
agents array · 2 items
[0] object · 3 fields
id
agent:corpus-assay-engine
type
software
label
Corpus assay engine
[1] object · 3 fields
id
agent:minimax-reader
type
software
label
MiniMax literature reader
source_run_id
reading-sci-2026-11-01
dsl_catalogue_fingerprint
343fb30756ba6ec3
capability_table_fingerprint
2cb3e42f047d2ecf
snapshot_id
ba34b49490d9bfaf
lineage object · 4 fields
parent_id
pmid:34123798
parent_hash
sha256:45f9fa58fc923493cbc1d408f89c29a241f108d8565c883948927f51e53a93bc
fork_of
null
gaps array · 5 items
[0]
execution.not_run
[1]
review.human_critique
[2]
review.independent_reader
[3]
review.machine_critique
[4]
step:obtain_source_data blocked on data:accession_absent
assays array · 1 item
[0] object · 11 fields
role
analysis
definition_id
survival_analysis
definition_version
f2132e96ae6c7a4e
required_operations array · 1 item
[0]
cox_ph
support_state
supported
source_hashes object · 1 field
dsl_catalogue
f2132e96ae6c7a4e
evidence array · 1 item
[0]
The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model.
order_basis
analysis_only
id
assay:1
Complete file
{"sci_version": "1.2", "schema": "https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json", "id": "pmid:34123798", "kind": "science-record", "revision": 6, "content_hash": "sha256:1ef0e142558dab1af77d1e9b0813c00be703fcb3b39a3b7a5e9ad03caa91a127", "created_at": "2026-11-01T15:41:38Z", "updated_at": "2026-11-01T21:25:30Z", "generator": {"name": "corpus-assay-engine", "run_id": "reading-sci-2026-11-01"}, "paper": {"state": "complete", "title": "Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades.", "doi": "10.3389/fonc.2021.650122", "pmid": "34123798", "authors": ["Xiaoyan Wang", "Bingchen Wu", "Zhengqing Yan", "Guoqiang Wang", "Shiqing Chen", "Jian Zeng", "Feng Tao", "Bichun Xu", "Honggang Ke", "Mei Li"], "journal": "Frontiers in oncology", "year": 2021, "abstract": "The common gamma receptor-dependent cytokines and their JAK-STAT pathways play important roles in T cell immunity and have been demonstrated to be related with response to immune checkpoint blockades (ICBs). PTPRD and PTPRT are phosphatases involved in JAK-STAT pathway. However, their clinical significance for non-small cell lung cancer (NSCLC) treated with ICBs is still unclear. Genomic and survival data of NSCLC patients administrated with anti-PD-1/PD-L1 or anti-CTLA-4 antibodies (Rizvi2015; Hellmann2018; Rizvi2018 Samstein2019) were retrieved from publicly accessible data. Genomic, survival and mRNA data of 1007 patients with NSCLC were obtained from The Cancer Genome Atlas (TCGA). PTPRD/PTPRT mutation was significantly associated with better progression-free survival (PFS) in three independent Rizvi2015, Hellmann2018 and Rizvi2018 cohorts. The median PFS for PTPRD/PTPRT mutant-type vs. wild-type NSCLC patients were not reached vs. 6.3 months (Rizvi2015, HR = 0.16; 95% CI, 0.02-1.17; P=0.03), 24.0 vs. 5.4 months (Hellmann2018, HR, 0.49; 95% CI, 0.26-0.94; P=0.03), 5.6 vs. 3.0 months (Rizvi2018, HR = 0.64; 95% CI, 0.44-0.92; P=0.01) and 6.8 vs. 3.5 months (Pooled cohort, HR, 0.54; 95% CI, 0.39-0.73; P<0.0001) respectively. PTPRD/PTPRT mutation was an independent predictive factor for PFS in pooled cohort (P = 0.01). Additionally, PTPRD/PTPRT mutation associated with better overall survival (OS) in Samstein2019 cohort (19 vs. 10 months, P=0.03). While similar clinical benefits were not observed in patients without ICBs treatment (TCGA cohort, P=0.78). In the further exploratory analysis, PTPRD/PTPRT mutation was significantly associated with increased tumor mutation burden and higher mRNA expression of JAK1 and STAT1. Gene Set Enrichment Analysis revealed prominent enrichment of signatures related to antigen processing and presentation in patients with PTPRD/PTPRT mutation. This work suggested that PTPRD/PTPRT mutation might be a potential positive predictor for ICBs in NSCLC. These results need to be further confirmed in future.", "claims": [{"id": "claim-method", "statement": "The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model.", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:34123798", "locator": "sections[5] \"Statistical Analyses\" paragraph 2", "quote": "The associations between PFS and various variables were examined by univariable and multivariable regression analysis."}, {"asset": "source:pmid:34123798", "locator": "sections[5] \"Statistical Analyses\" paragraph 2", "quote": "Hazard’s ratio (HR) was determined through a cox proportional hazards regression model."}], "state": "complete"}, {"id": "claim-data-access", "statement": "The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material .", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:34123798", "locator": "sections[13] \"Data Availability Statement\" paragraph 2", "quote": "The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material ."}], "state": "complete"}], "gaps": []}, "experiment": {"state": "partial", "objective": null, "steps": [{"id": "read_published_estimate", "order": 1, "name": "Read the published estimate from the source", "kind": "other", "state": "complete", "blocked_on": null, "description": "The claim, method and evidence span published with the source article.", "duration_hours": null, "parameters": {}, "inputs": ["source:pmid:34123798"], "outputs": ["the published estimate and its evidence"], "instruments": [], "reagents": []}, {"id": "obtain_source_data", "order": 2, "name": "Obtain the source data from the named repository", "kind": "data-preparation", "state": "blocked", "blocked_on": "data:accession_absent", "description": "The GEO series accession resolves and its sample accessions are listed. This lane did not download the dataset or read its licence.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the source data with its repository provenance"], "instruments": [], "reagents": []}, {"id": "run_analysis", "order": 3, "name": "Run the published analysis", "kind": "analysis", "state": "complete", "blocked_on": null, "description": "Apply the paper's statistical method to the resolved series and compare the result with the published target.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the replicated result and its comparison"], "instruments": [], "reagents": []}], "materials": [], "instruments": [], "reagents": [], "conditions": {}, "gaps": ["step:obtain_source_data blocked on data:accession_absent"]}, "data": {"state": "partial", "assets": [{"id": "source:pmid:34123798", "role": "manuscript", "format": "xml", "media_type": "application/xml", "uri": "https://doi.org/10.3389/fonc.2021.650122", "sha256": "sha256:a740dc3207dd79086d5d5e07b81b1b95669d53b687ba33ba9cc959038595d2f0", "bytes": 35969, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "10.3389/fonc.2021.650122", "version": null, "note": "Full article fetched from PMC; the checksum covers the rendered section body, not the original XML bytes.", "structure": {"pmcid": "PMC8192300", "source": "europe_pmc_fulltext", "coverage": "whole_body", "text_hash_scope": "rendered_section_body"}}, {"id": "asset:table:pmid:34123798:1", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:1c5700fd5ecbb8bbb34805eff0f42670849a8f7f9828b91851081ecc529874cb", "bytes": 1548, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[7]/table-wrap[1]#T1", "version": null, "note": "Baseline characteristics of NSCLC patients in Rizvi2015, Hellmann2018, Rizvi2018 and pooled cohorts.", "structure": {"pmcid": "PMC8192300", "section_index": 7, "section_title": "Association Between PTPRD/PTPRT Mutation and Better PFS in NSCLC Patients Who Received ICBs Therapy From Three Independent Cohorts", "row_count": 25, "column_count": 5}, "table": {"label": "Table 1", "caption": "Baseline characteristics of NSCLC patients in Rizvi2015, Hellmann2018, Rizvi2018 and pooled cohorts.", "rows": [["Characteristics", "Rizvi2015", "Hellmann2018", "Rizvi2018", "Pooled Cohort"], ["Total n", "34", "75", "240", "349"], ["Age, median (range)", "62.5 (41-80)", "66 (42-87)", "66 (22-92)", "65 (22-92)"], ["Sex", "", "", "", ""], ["Male", "16 (47%)", "37 (49%)", "118 (49%)", "171 (49%)"], ["Female", "18 (53%)", "38 (51%)", "122 (51%)", "178 (51%)"], ["Cancer type n (%)", "", "", "", ""], ["Adenocarcinoma", "34 (100%)", "59 (79%)", "186 (78%)", "279 (80%)"], ["Squamous", "0 (0%)", "16 (21%)", "34 (14%)", "50 (14%)"], ["Others", "0 (0%)", "0 (%)", "20 (8%)", "20 (6%)"], ["Agent", "", "", "", ""], ["PD-(L)1", "34 (100%)", "0 (0%)", "206(86%)", "240 (0%)"], ["PD-(L)1+CTLA-4", "0 (0%)", "75 (100%)", "34(14%)", "109 (100%)"], ["Smoking history, n (%)", "", "", "", ""], ["Current/former", "28 (82%)", "60 (80%)", "193 (80%)", "281 (80%)"], ["Never", "6 (18%)", "15 (20%)", "47 (20%)", "68 (20%)"], ["PDL1_expression", "", "", "", ""], ["≥1%", "24 (70%)", "45 (60%)", "43 (18%)", "112 (32%)"], ["0%", "6 (18%)", "25 (33%)", "41 (17%)", "72 (21%)"], ["Unknown", "4 (12%)", "5 (7%)", "156 (65%)", "165 (47%)"], ["Gene, n (%)", "", "", "", ""], ["PTPRD mutation", "3 (9%)", "16 (21%)", "30 (13%)", "49 (14%)"], ["PTPRT mutation", "2 (6%)", "9 (12%)", "23 (10%)", "34 (10%)"], ["PTPRD/PTPRT mutation", "5 (15%)", "22 (29%)", "47 (20%)", "74 (21%)"], ["PTPRD/PTPRT wild-type", "29 (85%)", "53 (71%)", "193 (80%)", "275 (79%)"]], "row_count": 25, "column_count": 5, "numeric_cells": 79, "header_rows": 1, "locator": "section[7]/table-wrap[1]#T1"}}, {"id": "asset:table:pmid:34123798:2", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:d4b7f9d1b42adcac7d5162b43c12d7ec8abdd638f08381e803f51d4bbe75dfdc", "bytes": 2943, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[7]/table-wrap[2]#T2", "version": null, "note": "Univariable and multivariable analyses of progression-free survival.", "structure": {"pmcid": "PMC8192300", "section_index": 7, "section_title": "Association Between PTPRD/PTPRT Mutation and Better PFS in NSCLC Patients Who Received ICBs Therapy From Three Independent Cohorts", "row_count": 39, "column_count": 5}, "table": {"label": "Table 2", "caption": "Univariable and multivariable analyses of progression-free survival.", "rows": [["Rizvi2015"], ["Parameter", "Univariable Analysis", "Multivariable Analysis"], ["HR (95%CI)", "P value", "HR (95%CI)", "P value"], ["Age ≥65 vs. <65 y", "0.82 (0.33-2.01)", "0.66", "1.05 (0.33-3.38)", "0.93"], ["Male vs. female", "1.75 (0.75-4.07)", "0.20", "1.09 (0.36-3.36)", "0.88"], ["Current or former vs. never smoker", "0.60 (0.22-1.64)", "0.32", "0.67 (0.16-2.91)", "0.60"], ["TMB≥median vs. <median", "0.21 (0.08-0.55)", "0.002", "0.20 (0.06-0.67)", "0.01"], ["PD-L1 status ≥1% vs. <1%", "0.38 (0.14-1.01)", "0.05", "0.98 (0.33-2.98)", "0.98"], ["PTPRD/PTPRT mutant vs. wild", "0.16 (0.02-1.17)", "0.07", "0.23 (0.03-2.04)", "0.18"], ["Lines of therapy ≥3 vs. <3", "1.24 (0.53-2.91)", "0.62", "1.79 (0.46-6.93)", "0.40"], ["Hellmann2018"], ["Parameter", "Univariable Analysis", "Multivariable Analysis"], ["HR (95%CI)", "P value", "HR (95%CI)", "P value"], ["Age ≥65 vs. <65 y", "0.89 (0.51-1.55)", "0.67", "0.71 (0.37-1.36)", "0.31"], ["Male vs. female", "1.03 (0.59-1.80)", "0.92", "1.03 (0.55-1.91)", "0.94"], ["Current or former vs. never smoker", "0.70 (0.36-1.36)", "0.29", "0.78 (0.37-1.64)", "0.51"], ["TMB≥median vs. <median", "0.49 (0.28-0.87)", "0.02", "0.59 (0.28-1.22)", "0.16"], ["PD-L1 status ≥1% vs. <1%", "0.86 (0.47-1.59)", "0.63", "1.04 (0.52-2.07)", "0.92"], ["PTPRD/PTPRT mutant vs. wild", "0.47 (0.24-0.92)", "0.03", "0.59 (0.24-1.47)", "0.25"], ["Rizvi2018"], ["Parameter", "Univariable Analysis", "Multivariable Analysis"], ["HR (95%CI)", "P value", "HR (95%CI)", "P value"], ["Age ≥65 vs. <65 y", "1.14 (0.86-1.52)", "0.35", "1.12 (0.69-1.81)", "0.66"], ["Male vs. female", "1.09 (0.83-1.44)", "0.54", "0.88 (0.53-1.44)", "0.60"], ["Current or former vs. never smoker", "0.69 (0.49-0.97)", "0.03", "0.59 (0.30-1.17)", "0.13"], ["TMB≥median vs. <median", "0.65 (0.49-0.86)", "0.003", "0.94 (0.52-1.69)", "0.84"], ["PD-L1 status ≥1% vs. <1%", "0.58 (0.36-0.92)", "0.02", "0.52 (0.31-0.88)", "0.01"], ["PTPRD/PTPRT mutant vs. wild", "0.64 (0.44-0.92)", "0.02", "0.43 (0.20-0.92)", "0.03"], ["Lines of therapy ≥3 vs. <3", "1.37 (1.00-1.88)", "0.05", "1.25 (0.70-2.20)", "0.45"], ["All NSCLC in pooled cohort"], ["Parameter", "Univariable Analysis", "Multivariable Analysis"], ["HR (95%CI)", "P value", "HR (95%CI)", "P value"], ["Age ≥65 vs. <65 y", "1.06 (0.83-1.35)", "0.64", "0.95 (0.67-1.35)", "0.78"], ["Male vs. female", "1.13 (0.89-1.44)", "0.31", "1.00 (0.71-1.41)", "0.99"], ["Current or former vs. never smoker", "0.70 (0.52-0.93)", "0.01", "0.63 (0.41-0.97)", "0.04"], ["TMB≥median vs. <median", "0.56 (0.44-0.72)", "<0.001", "0.62 (0.42-0.92)", "0.02"], ["PD-L1 status ≥1% vs. <1%", "0.60 (0.43-0.84)", "0.003", "0.67 (0.47-0.96)", "0.03"], ["PTPRD/PTPRT mutant vs. wild", "0.54 (0.39-0.73)", "<0.001", "0.52 (0.31-0.87)", "0.01"], ["lines of therapy ≥3 vs. <3", "0.88 (0.69-1.12)", "0.30", "0.80 (0.56-1.13)", "0.21"]], "row_count": 39, "column_count": 5, "numeric_cells": 130, "header_rows": 3, "locator": "section[7]/table-wrap[2]#T2"}}], "gaps": []}, "analysis": {"state": "complete", "methods": [{"id": "method-1", "family": "survival_analysis", "specific": "cox_proportional_hazards", "label": "Survival analysis", "dsl_operations": ["cox_ph"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 1.0, "band": "reordered", "quote": "The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model."}}, {"id": "method-2", "family": "survival_analysis", "specific": "kaplan_meier", "label": "Survival analysis", "dsl_operations": ["survival_km"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.8, "band": "high", "quote": "Kaplan-Meier"}}], "targets": [], "gaps": []}, "capability": {"state": "complete", "requirements": [{"capability_id": "capability:computational_analysis", "label": "Computational analysis platform", "assay_families": ["meta_analysis", "machine_learning", "survival_analysis", "statistical_regression", "pca", "molecular_docking", "network_analysis", "differential_expression", "gwas"], "availability_state": "owned", "tier_unlocked": "R1", "candidate": "Automated Assays Laravel application and simulated adapters"}], "gaps": []}, "readiness": {"state": "blocked", "tier": "R4", "blocking_axis": "data", "blocked_on": "data:accession_absent", "axes": {"method": {"tier": "R1", "expressible": true, "required_operations": ["cox_ph"], "missing_operations": [], "basis": "The paper names the method it used and the corpus's method extractor maps it onto the DSL catalogue: cox_proportional_hazards."}, "capability": {"tier": "R1", "capability_id": "capability:computational_analysis", "availability_state": "owned", "basis": "The computational analysis is owned. The physical bench the paper used is not, so a physical validation cannot be run here."}, "data": {"tier": "R4", "reachable": false, "accessions": [], "resolved_accessions": [], "statements": ["The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material ."], "basis": "The paper names no accession to its source data, so the data has to come from the authors."}}, "can_run": {"dsl_operations": ["cox_ph"], "assets": ["source:pmid:34123798", "asset:table:pmid:34123798:1", "asset:table:pmid:34123798:2"], "steps": ["run_analysis"]}, "must_build": {"dsl_operations": [], "converters": [], "readers": [], "capabilities": [], "data_gaps": ["data:geo:None"]}, "gaps": ["data:accession_absent"]}, "review": {"state": "partial", "machine_critique": {"kind": "extraction_review", "reader": {"model": "MiniMax-M3.1-Flash", "provider": "minimax", "provider_family": "minimax", "read_at": "2026-10-31T18:30:51Z", "independence": "single_reader"}, "evidence_check": {"method": "reordered", "availability": "verbatim"}, "calls": 3, "usage": {"prompt_tokens": 30901, "completion_tokens": 1352, "cached_tokens": 784}}, "human_critique": null, "stages": [{"id": "extraction", "state": "complete", "reader": "MiniMax-M3.1-Flash", "provider": "minimax"}], "gaps": ["review.independent_reader", "review.machine_critique", "review.human_critique"]}, "execution": {"state": "absent", "status": "not_run", "mode": null, "runs": [], "gaps": ["execution.not_run"]}, "provenance": {"entities": [{"id": "pmid:34123798", "type": "paper", "label": "pmid:34123798"}, {"id": "source:pmid:34123798", "type": "manuscript", "label": "PMID 34123798 full text"}, {"id": "data:geo:None", "type": "dataset", "label": "GEO None"}], "activities": [{"id": "activity-reading-sci-2026-11-01", "type": "classification", "used": [{"id": "pmid:34123798", "type": "paper", "label": "pmid:34123798"}, {"id": "source:pmid:34123798", "type": "manuscript", "label": "PMID 34123798 full text"}, {"id": "data:geo:None", "type": "dataset", "label": "GEO None"}], "agent": "agent:corpus-assay-engine"}, {"id": "activity-read-34123798", "type": "extraction", "used": ["source:pmid:34123798"], "agent": "agent:minimax-reader"}, {"id": "activity-resolve-None", "type": "accession_resolution", "used": ["data:geo:None"], "agent": "agent:corpus-assay-engine"}], "agents": [{"id": "agent:corpus-assay-engine", "type": "software", "label": "Corpus assay engine"}, {"id": "agent:minimax-reader", "type": "software", "label": "MiniMax literature reader"}], "source_run_id": "reading-sci-2026-11-01", "dsl_catalogue_fingerprint": "343fb30756ba6ec3", "capability_table_fingerprint": "2cb3e42f047d2ecf", "snapshot_id": "ba34b49490d9bfaf"}, "lineage": {"parent_id": "pmid:34123798", "parent_hash": "sha256:45f9fa58fc923493cbc1d408f89c29a241f108d8565c883948927f51e53a93bc", "fork_of": null, "generation": 5}, "gaps": ["execution.not_run", "review.human_critique", "review.independent_reader", "review.machine_critique", "step:obtain_source_data blocked on data:accession_absent"], "assays": [{"role": "analysis", "definition_id": "survival_analysis", "definition_version": "f2132e96ae6c7a4e", "definition_digest": null, "required_operations": ["cox_ph"], "support_state": "supported", "source_hashes": {"dsl_catalogue": "f2132e96ae6c7a4e"}, "confidence": 1.0, "evidence": ["The associations between PFS and various variables were examined by univariable and multivariable regression analysis. Hazard’s ratio (HR) was determined through a cox proportional hazards regression model."], "order_basis": "analysis_only", "id": "assay:1"}]}